表紙
市場調查報告書
商品編碼
1087894

全球神經修復和再生市場:副產品(神經調節裝置(深部腦刺激,雜散神經刺激),生物材料(神經導管/包裹)),應用(神經切除/移植,幹細胞治療)到2027預測

Nerve Repair & Regeneration Market by Products(Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials(Nerve Conduits, Nerve Wraps), Application(Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast -2027

出版日期: | 出版商: MarketsandMarkets | 英文 225 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球神經修復和再生市場預計將從 2022 年的 65 億美元增長到 12.1% 的複合年增長率,到 2027 年達到 116 億美元。

市場的增長將受到政府對神經疾病相關研究的支出以及市場進入者對神經調節/神經刺激設備和生物材料的研發投資增加的推動。

在區域市場中,由於人口眾多、經濟增長、衛生基礎設施和成本改善以及對神經系統疾病的高度認識等因素,預計亞太地區將在預測期內以最高的增長率增長。

本報告調查全球神經修復和再生市場,並提供有關市場動態、COVID-19 影響、細分/區域市場分析、競爭條件和主要公司概況的信息。

目錄

第一章介紹

第二章調查方法

第 3 章執行摘要

第 4 章重要考慮

第 5 章市場概述

  • 市場動態
    • 促進因素
    • 市場機會
    • 挑戰
  • COVID-19 對市場的影響
  • 價格分析

第 6 章按產品:神經修復和再生市場

  • 神經刺激和調節裝置
    • 內神經刺激和神經調節裝置
    • 外部神經刺激和神經調節裝置
  • 生物材料
    • 神經傳導
    • 神經包裹

第7章按用途:神經修復和再生市場

  • 神經刺激與調節
    • 內神經刺激和神經調節
    • 外部神經刺激和神經調節
  • 神經修復再生生物材料
    • 直接神經修復/神經病變
    • 神經移植
    • 幹細胞療法

第8章區域:神經修復和再生市場

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他
  • 其他領域
    • 拉丁美洲
    • 中東/非洲

第9章競爭態勢

  • 概覽
  • 主要公司/領先公司的戰略
  • 市場份額分析(2021 年)
  • 企業評價象限(主要公司)
  • 企業評估象限(SME/Startup)
  • 競爭基準
  • 競爭形勢和趨勢

第 10 章公司簡介

  • 主要公司
    • MEDTRONIC, PLC.
    • BOSTON SCIENTIFIC CORPORATION
    • ABBOTT LABORATORIES
    • AXOGEN CORPORATION.
    • BAXTER
    • LIVANOVA PLC
    • INTEGRA LIFESCIENCES
    • NEURONETICS INC.
    • NEVRO CORP.
    • NEUROPACE INC.
    • POLYGANICS
    • SOTERIX MEDICAL INC.
    • SYNAPSE BIOMEDICAL INC
    • ALEVA NEUROTHERAPEUTICS SA
    • COLLAGEN MATRIX INC
    • KERIMEDICAL
  • 主要企業
    • BIOWAVEGO USA
    • NEUROSIGMA, INC.
    • TVNS TECHNOLOGIES GMBH
    • GIMER MEDICAL
    • CHECKPOINT SURGICAL INC.
    • RENISHAW PLC.
    • ALAFAIR BIOSCIENCES, INC.
    • ELECTROCORE, INC.

第11章 附錄

目錄
Product Code: MD 3642

The global nerve repair & regeneration market is expected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 12.1%. The growth in this market is driven by increasing research expenditure on the neurological disorders by the government, the increasing R&D investments by the market players into the neuromodulation and neurostimulation devices and the biomaterials. Also, the expanding geriatric population base dries the growth of the market by placing more demand of the nerve repair and regeneration products.

"The biomaterial as segment is anticipated to grow at the fastest growth rate during the forecast period."

Based on product type, the nerve repair and regenerations market is segmented into neurostimulation and neuromodulation devices and biomaterials. The biomaterials segment is expected to register the highest CAGR which is driven by the research investments, and R&D expenditure by the government and market players.

"The internal neurostimulation and neuromodulation segment is accounted for the largest share during the analysis period."

Based on the neurostimulation and neuromodulation application, the nerve repair & regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation neuromodulation segment is held the largest share during the forecast period owing to the rising cases of nerve related injuries and the high incidence of neurological disorders.

"Asia Pacific is estimated to register the highest CAGR during the study period. North America is expected to dominate the market share"

In this report, the nerve repair & regeneration market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (Middle East & Africa and Latin America). In 2021, North America held the largest share of the market owing to the presence of the leading players and advanced healthcare infrastructure.

The market in Asia Pacific is projected to grow at the highest growth rate during the forecast period owing to the massive population base, increasing economical growth, improving healthcare infrastructure and healthcare expenditure, high reverence of the neurologic diseases and the rising demand

Breakdown of primary supply-side interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
  • By Designation: C-level (30%), Director-level (34%), and Others (36%)
  • By Region: North America (50%), Europe (32%), AsiaPacific (10%), and Rest of the World (8%)

List of players profiled in this report:

  • Medtronic, plc. (Ireland)
  • Boston Scientific Corporation (US),
  • Abbott Laboratories (US)
  • Axogen Corporation (US)
  • Baxter (US)
  • LivaNova PLC (UK)
  • Integra LifeSciences (US)
  • Neuronetics Inc. (US)
  • Nevro Corp (US)
  • NeuroPace Inc. (US)
  • Polyganics (Netherlands)
  • Soterix Medical Inc (US)
  • Synapse Biomedical Inc. (US)
  • Aleva Neurotherapeutics SA (Switzerland)
  • Collagen Matrix Inc. (US)
  • KeriMedical (Switzerland)
  • BioWaveGO USA (US)
  • NeuroSigma Inc. (US)
  • tVNS Technologies GmbH (Germany)
  • GiMer Medical (Taiwan)
  • Checkpoint Surgical Inc. (US)
  • Renishaw PLC (UK)
  • Alafair Biosciences, Inc. (US)
  • electroCore, Inc. (US)

Research Coverage

This report studies the nerve repair & regeneration market based on product, application and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total nerve repair & regeneration market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the nerve repair and regeneration offered by the top 16 players in the market. The report analyzes the nerve repair & regeneration market by product and region
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various nerve repair and regeneration across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the nerve repair & regeneration market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the nerve repair & regeneration market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 NERVE REPAIR & REGENERATION MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
    • TABLE 2 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES MADE
  • 1.7 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
    • TABLE 3 KEY DATA FROM PRIMARY SOURCES
      • 2.1.2.2 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 NERVE REPAIR & REGENERATION MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC PLC
    • FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF NERVE REPAIR & REGENERATION PRODUCTS
    • FIGURE 6 CAGR PROJECTIONS
    • FIGURE 7 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY
    • 2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 4 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 9 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)

4 PREMIUM INSIGHTS

  • 4.1 NERVE REPAIR & REGENERATION MARKET OVERVIEW
  • 4.2 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT & COUNTRY (2021)
  • 4.3 NERVE REPAIR & REGENERATION MARKET, BY REGION (2022 VS. 2027)
    • FIGURE 19 NORTH AMERICA TO DOMINATE THE NERVE REPAIR & REGENERATION MARKET DURING THE FORECAST PERIOD
  • 4.4 NERVE REPAIR & REGENERATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 NERVE REPAIR & REGENERATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 High incidence of nerve injuries
      • 5.2.1.2 Rising focus on neuromodulation & neurostimulation technologies
      • 5.2.1.3 Rising geriatric population and the subsequent increase in the prevalence of neurological disorders
      • 5.2.1.4 Rising government support for research on neurological disorders
    • FIGURE 22 FUNDING FOR RESEARCH BY THE NIH (US)
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Emerging markets
    • FIGURE 23 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA, 2012-2019
      • 5.2.2.2 Advances in stem cell therapy in nerve repair & regeneration
      • 5.2.2.3 Growing research projects in neurology
    • FIGURE 24 RESEARCH PAPERS PUBLISHED (2011-2021)
    • TABLE 5 INDICATIVE LIST: NEUROMODULATION CLINICAL TRAILS
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Donor-site morbidity
      • 5.2.3.2 Difficulties in treating large nerve gaps
      • 5.2.3.3 Stringent regulatory frameworks and time-consuming approval processes
      • 5.2.3.4 Greater preference for drug therapies over nerve repair & regeneration products
      • 5.2.3.5 Shortage of trained professionals
      • 5.2.3.6 Product recalls
    • TABLE 6 MAJOR PRODUCT RECALLS
  • 5.3 IMPACT OF COVID-19 ON THE NERVE REPAIR & REGENERATION MARKET
    • FIGURE 25 REVENUE OF NEUROMODULATION SEGMENT BY THE TOP THREE PLAYERS, 2019-2021 (USD MILLION)
  • 5.4 PRICING ANALYSIS
    • TABLE 7 AVERAGE SELLING PRICES OF NERVE WRAP AND NERVE CONDUIT
    • TABLE 8 AVERAGE SELLING PRICES OF NERVE WRAP OF KEY COMPANIES
    • TABLE 9 AVERAGE SELLING PRICES OF NERVE CONDUITS OF KEY COMPANIES

6 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 10 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018-2020 (USD MILLION)
    • TABLE 11 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
  • 6.2 NEUROSTIMULATION AND NEUROMODULATION DEVICES
    • TABLE 12 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 13 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 14 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 15 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.2.1 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES
    • TABLE 16 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 17 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 18 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 19 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.1.1 Spinal cord stimulation devices
        • 6.2.1.1.1 Increasing incidence of spinal cord injuries to support the growth of this segment
    • TABLE 20 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 21 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.1.2 Deep brain stimulation devices
        • 6.2.1.2.1 Rising incidence of neurodegenerative diseases among the senior population drives the growth of this segment
    • TABLE 22 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 23 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.1.3 Vagus nerve stimulation devices
        • 6.2.1.3.1 Increasing incidence of epilepsy to support the market growth for VNS devices
    • TABLE 24 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 25 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.1.4 Sacral nerve stimulation devices
        • 6.2.1.4.1 Increasing incidence of urological disorders to drive the growth of this segment
    • TABLE 26 SACRAL NERVE STIMULATION DEVICES OFFERED BY SOME MARKET PLAYERS
    • TABLE 27 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 28 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.1.5 Gastric electrical stimulation devices
        • 6.2.1.5.1 GES is mainly used for the treatment of GERD and gastroparesis
    • TABLE 29 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 30 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.2.2 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES
    • TABLE 31 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 32 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 33 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION BY REGION, 2018-2020 (USD MILLION)
    • TABLE 34 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.2.1 Transcutaneous electrical nerve stimulation devices
        • 6.2.2.1.1 Extensive use in healthcare and low costs to support the growth of this segment
    • TABLE 35 TENS DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 36 TENS DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.2.2 Transcranial Magnetic Stimulation Devices
        • 6.2.2.2.1 Minimal patient discomfort associated with TMS to support the adoption of TMS devices
    • TABLE 37 TMS DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 38 TMS DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 6.2.2.3 Respiratory Electric Stimulation Devices
        • 6.2.2.3.1 Increasing incidence of spinal cord injuries to support the growth of this segment
    • TABLE 39 RES DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 40 RES DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
  • 6.3 BIOMATERIALS
    • TABLE 41 BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 42 BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • TABLE 43 BIOMATERIALS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 44 BIOMATERIALS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.3.1 NERVE CONDUITS
      • 6.3.1.1 Increasing research in the field of nerve repair to support segment growth
    • TABLE 45 NERVE CONDUITS OFFERED BY SOME MARKET PLAYERS
    • TABLE 46 NERVE CONDUITS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 47 NERVE CONDUITS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.3.2 NERVE WRAPS
      • 6.3.2.1 Increasing incidence of peripheral injuries to drive the growth of this segment
    • TABLE 48 NERVE WRAPS OFFERED BY SOME MARKET PLAYERS
    • TABLE 49 NERVE WRAPS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 50 NERVE WRAPS MARKET, BY REGION, 2021-2027 (USD MILLION)

7 NERVE REPAIR & REGENERATION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 NEUROSTIMULATION & NEUROMODULATION
    • TABLE 51 NEUROSTIMULATION & NEUROMODULATION MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 52 NEUROSTIMULATION & NEUROMODULATION MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 53 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 54 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION, 2021-2027 (USD MILLION)
    • 7.2.1 INTERNAL NEUROSTIMULATION & NEUROMODULATION
      • 7.2.1.1 Minimally invasive nature and reversibility to support the growth of this segment
    • TABLE 55 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 56 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 7.2.2 EXTERNAL NEUROSTIMULATION & NEUROMODULATION
      • 7.2.2.1 Rising cases of noninvasive procedures to ensure the growth of this segment
    • TABLE 57 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 58 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2021-2027 (USD MILLION)
  • 7.3 NERVE REPAIR & REGENERATION BIOMATERIALS
    • TABLE 59 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 60 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • 7.3.1 DIRECT NERVE REPAIR/NEURORRHAPHY
    • TABLE 61 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 62 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 63 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 64 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 7.3.1.1 Epineural repair
        • 7.3.1.1.1 Short operating times, ease, and minimal suturing requirements to drive the growth of this segment
    • TABLE 65 EPINEURAL REPAIR MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 66 EPINEURAL REPAIR MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 7.3.1.2 Perineural repair
        • 7.3.1.2.1 Perineural repair is a highly complex surgery, which has affected its prospects in this market
    • TABLE 67 PERINEURAL REPAIR MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 68 PERINEURAL REPAIR MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 7.3.1.3 Group fascicular repair
        • 7.3.1.3.1 Long procedural time to restrain the growth of this market
    • TABLE 69 GROUP FASCICULAR REPAIR MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 70 GROUP FASCICULAR REPAIR MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 7.3.2 NERVE GRAFTING
    • TABLE 71 NERVE GRAFTING MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 72 NERVE GRAFTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 73 NERVE GRAFTING MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 74 NERVE GRAFTING MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 7.3.2.1 Autografts
        • 7.3.2.1.1 Autografts are considered the gold standard for nerve gap treatment
    • TABLE 75 AUTOGRAFTS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 76 AUTOGRAFTS MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 7.3.2.2 Allografts
        • 7.3.2.2.1 Benefits of allografts over autograft usage to drive the growth of this segment
    • TABLE 77 ALLOGRAFTS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 78 ALLOGRAFTS MARKET, BY REGION, 2021-2027 (USD MILLION)
      • 7.3.2.3 Xenografts
        • 7.3.2.3.1 Need for immunosuppression associated with xenograft use to restrain the growth of this segment
    • TABLE 79 XENOGRAFTS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 80 XENOGRAFTS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 7.3.3 STEM CELL THERAPY
      • 7.3.3.1 The high future growth prospects counterbalance the low penetration of stem cell therapy
    • TABLE 81 STEM CELL THERAPY MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 82 STEM CELL THERAPY MARKET, BY REGION, 2021-2027 (USD MILLION)

8 NERVE REPAIR & REGENERATION MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 83 NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 84 NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021-2027 (USD MILLION)
  • 8.2 NORTH AMERICA
    • TABLE 85 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 86 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 87 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018-2020 (USD MILLION)
    • TABLE 88 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
    • TABLE 89 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 90 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 91 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 92 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 93 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 94 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 95 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 96 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 97 NORTH AMERICA: BIOMATERIALS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 98 NORTH AMERICA: BIOMATERIALS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 99 NORTH AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 100 NORTH AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • TABLE 101 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 102 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 103 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
    • TABLE 104 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
    • TABLE 105 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 106 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 The high prevalence of neurological disorders drives the demand for nerve repair & regeneration products in the US
    • TABLE 107 COMPANY PRODUCTS THAT RECEIVED FDA APPROVAL IN THE US
    • TABLE 108 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 109 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 110 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 111 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 112 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 113 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 114 US: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 115 US: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Rising health expenditure and increasing disease prevalence will drive market growth
    • TABLE 116 NEUROLOGICAL CONDITIONS IN CANADA
    • TABLE 117 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 118 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 119 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 120 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 121 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 122 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 123 CANADA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 124 CANADA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 125 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 126 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 127 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018-2020 (USD MILLION)
    • TABLE 128 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
    • TABLE 129 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 130 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 131 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 132 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 133 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 134 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 135 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 136 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 137 EUROPE: BIOMATERIALS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 138 EUROPE: BIOMATERIALS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 139 EUROPE: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 140 EUROPE: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • TABLE 141 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 142 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 143 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 144 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 145 EUROPE: BIOMATERIALS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 146 EUROPE: BIOMATERIALS MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Rising healthcare expenditure and favorable reimbursement policies to ensure strong market growth
    • TABLE 147 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 148 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 149 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 150 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 151 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 152 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 153 GERMANY: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 154 GERMANY: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.3.2 UK
      • 8.3.2.1 Government initiatives to drive the growth of the nerve repair & regeneration market in the UK
    • TABLE 155 PRODUCTS RECEIVED CE APPROVAL
    • TABLE 156 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 157 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 158 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 159 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 160 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 161 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 162 UK: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 163 UK: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Favorable healthcare reforms to support the market growth in France
    • TABLE 164 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 165 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 166 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 167 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 168 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 169 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 170 FRANCE: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 171 FRANCE: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Easy access to healthcare services has supported the demand for nerve repair & regeneration products in Italy
    • TABLE 172 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 173 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 174 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 175 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 176 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 177 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 178 ITALY: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 179 ITALY: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 The growing geriatric population and the subsequent increase in the incidence of neurological disorders drive the market growth
    • TABLE 180 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 181 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 182 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 183 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 184 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 185 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 186 SPAIN: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 187 SPAIN: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 188 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2017 VS. 2050
    • TABLE 189 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 190 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 191 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 192 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 193 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 194 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 195 ROE: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 196 ROE: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • TABLE 197 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 198 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018-2020 (USD MILLION)
    • TABLE 200 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
    • TABLE 201 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 202 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 203 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 204 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 205 ASIA PACIFIC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 206 ASIA PACIFIC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 207 ASIA PACIFIC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 208 ASIA PACIFIC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 209 ASIA PACIFIC: BIOMATERIALS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 210 ASIA PACIFIC: BIOMATERIALS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 211 ASIA PACIFIC: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 212 ASIA PACIFIC: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • TABLE 213 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 214 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 215 ASIA PACIFIC: BIOMATERIALS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 216 ASIA PACIFIC: BIOMATERIALS MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • 8.4.1 JAPAN
      • 8.4.1.1 Japan dominates the Asia Pacific market for nerve repair & regeneration due to its high geriatric population
    • TABLE 217 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 218 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 219 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 220 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 221 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 222 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 223 JAPAN: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 224 JAPAN: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 Rising healthcare expenditure and growing disease prevalence to ensure strong market growth
    • FIGURE 28 CHINA: CURRENT HEALTH EXPENDITURE PER CAPITA (CURRENT USD)
    • TABLE 225 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 226 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 227 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 228 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 229 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 230 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 231 CHINA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 232 CHINA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 Changing government policies to have a positive impact on the market growth for nerve repair & regeneration
    • TABLE 233 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 234 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 235 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 236 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 237 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 238 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 239 INDIA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 240 INDIA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.4.4 REST OF ASIA PACIFIC (ROAPAC)
    • TABLE 241 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 242 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 243 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 244 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 245 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 246 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 247 ROAPAC: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 248 ROAPAC: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
  • 8.5 REST OF THE WORLD (ROW)
    • TABLE 249 ROW: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 250 ROW: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 251 ROW: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018-2020 (USD MILLION)
    • TABLE 252 ROW: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
    • TABLE 253 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 254 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 255 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 256 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 257 ROW: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 258 ROW: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 259 ROW: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 260 ROW: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 261 ROW: BIOMATERIALS MARKET, BY REGION, 2018-2020 (USD MILLION)
    • TABLE 262 ROW: BIOMATERIALS MARKET, BY REGION, 2021-2027 (USD MILLION)
    • TABLE 263 ROW: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 264 ROW: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • TABLE 265 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 266 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 267 ROW: BIOMATERIALS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
    • TABLE 268 ROW: BIOMATERIALS MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • 8.5.1 LATIN AMERICA
      • 8.5.1.1 High incidence rate of Parkinson's disease to support the market growth
    • FIGURE 29 POPULATION AGED 65 YEARS AND ABOVE (AS A PERCENTAGE OF THE TOTAL POPULATION), 2013-2018
    • TABLE 269 LATIN AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 270 LATIN AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 271 LATIN AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 272 LATIN AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 273 LATIN AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 274 LATIN AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 275 LATIN AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 276 LATIN AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)
    • 8.5.2 MIDDLE EAST & AFRICA
      • 8.5.2.1 Lack of health awareness and poor reimbursement policies to restrict the market growth
    • TABLE 277 MIDDLE EAST & AFRICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 278 MIDDLE EAST & AFRICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 279 MIDDLE EAST & AFRICA:INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 280 MIDDLE EAST & AFRICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 281 MIDDLE EAST & AFRICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018-2020 (USD MILLION)
    • TABLE 282 MIDDLE EAST & AFRICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 283 MIDDLE EAST & AFRICA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018-2020 (USD MILLION)
    • TABLE 284 MIDDLE EAST & AFRICA: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 285 OVERVIEW OF THE STRATEGIES ADOPTED BY KEY PLAYERS IN THE NERVE REPAIR & REGENERATION MARKET (2018 TO 2022)
  • 9.3 MARKET SHARE ANALYSIS, 2021
    • FIGURE 30 GLOBAL NERVE REPAIR & REGENERATION MARKET SHARE ANALYSIS, 2021
    • TABLE 286 NERVE REPAIR & REGENERATION MARKET: DEGREE OF COMPETITION
  • 9.4 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
    • 9.4.1 STARS
    • 9.4.2 PERVASIVE PLAYERS
    • 9.4.3 EMERGING LEADERS
    • 9.4.4 PARTICIPANTS
    • FIGURE 31 NERVE REPAIR & REGENERATION MARKET (GLOBAL): COMPANY EVALUATION QUADRANT, 2021
  • 9.5 COMPANY EVALUATION QUADRANT (SMES/STARTUPS)
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 RESPONSIVE COMPANIES
    • 9.5.3 STARTING BLOCKS
    • 9.5.4 DYNAMIC COMPANIES
    • FIGURE 32 NERVE REPAIR & REGENERATION MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
  • 9.6 COMPETITIVE BENCHMARKING
    • 9.6.1 COMPANY PRODUCT FOOTPRINT (27 COMPANIES)
    • 9.6.2 COMPANY REGIONAL FOOTPRINT
    • 9.6.3 COMPANY FOOTPRINT
  • 9.7 COMPETITIVE SITUATION AND TRENDS
    • 9.7.1 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 287 PRODUCT LAUNCHES AND APPROVALS, 2018-2022
    • 9.7.2 DEALS
    • TABLE 288 DEALS, 2018-2022
    • 9.7.3 OTHER DEVELOPMENTS
    • TABLE 289 OTHER DEVELOPMENTS, 2018-2022

10 COMPANY PROFILES

  • 10.1 KEY PLAYERS
  • (Business overview, Products offered, Recent developments, MNM Views, Key strengths/right to win, Strategic choices made, and Weaknesses and competitive threats)**
    • 10.1.1 MEDTRONIC, PLC.
    • TABLE 290 MEDTRONIC PLC: BUSINESS OVERVIEW
    • FIGURE 33 MEDTRONIC PLC: COMPANY SNAPSHOT (2021)
    • 10.1.2 BOSTON SCIENTIFIC CORPORATION
    • TABLE 291 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
    • FIGURE 34 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021)
    • 10.1.3 ABBOTT LABORATORIES
    • TABLE 292 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • 10.1.4 AXOGEN CORPORATION.
    • TABLE 293 AXOGEN CORPORATION.: BUSINESS OVERVIEW
    • FIGURE 36 AXOGEN CORPORATION.: COMPANY SNAPSHOT (2021)
    • 10.1.5 BAXTER
    • TABLE 294 BAXTER: BUSINESS OVERVIEW
    • FIGURE 37 BAXTER: COMPANY SNAPSHOT (2021)
    • 10.1.6 LIVANOVA PLC
    • TABLE 295 LIVANOVA PLC: BUSINESS OVERVIEW
    • FIGURE 38 LIVANOVA PLC: COMPANY SNAPSHOT (2021)
    • 10.1.7 INTEGRA LIFESCIENCES
    • TABLE 296 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
    • FIGURE 39 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021)
    • 10.1.8 NEURONETICS INC.
    • TABLE 297 NEURONETICS INC.: BUSINESS OVERVIEW
    • FIGURE 40 NEURONETICS INC.: COMPANY SNAPSHOT (2021)
    • 10.1.9 NEVRO CORP.
    • TABLE 298 NEVRO CORP.: BUSINESS OVERVIEW
    • FIGURE 41 NEVRO CORP.: COMPANY SNAPSHOT (2021)
    • 10.1.10 NEUROPACE INC.
    • TABLE 299 NEUROPACE INC.: BUSINESS OVERVIEW
    • FIGURE 42 NEUROPACE INC.: COMPANY SNAPSHOT (2021)
    • 10.1.11 POLYGANICS
    • TABLE 300 POLYGANICS: BUSINESS OVERVIEW
    • 10.1.12 SOTERIX MEDICAL INC.
    • TABLE 301 SOTERIX MEDICAL INC.: BUSINESS OVERVIEW
    • 10.1.13 SYNAPSE BIOMEDICAL INC
    • TABLE 302 SYNAPSE BIOMEDICAL INC: BUSINESS OVERVIEW
    • 10.1.14 ALEVA NEUROTHERAPEUTICS SA
    • TABLE 303 ALEVA NEUROTHERAPEUTICS: BUSINESS OVERVIEW
    • 10.1.15 COLLAGEN MATRIX INC
    • TABLE 304 COLLAGEN MATRIX INC: BUSINESS OVERVIEW
    • 10.1.16 KERIMEDICAL
    • TABLE 305 KERIMEDICAL: BUSINESS OVERVIEW
  • 10.2 OTHER PLAYERS
    • 10.2.1 BIOWAVEGO USA
    • TABLE 306 BIOWAVEGO USA: COMPANY OVERVIEW
    • 10.2.2 NEUROSIGMA, INC.
    • TABLE 307 NEUROSIGMA, INC.: COMPANY OVERVIEW
    • 10.2.3 TVNS TECHNOLOGIES GMBH
    • TABLE 308 TVNS TECHNOLOGIES GMBH: COMPANY OVERVIEW
    • 10.2.4 GIMER MEDICAL
    • TABLE 309 GIMER MEDICAL: COMPANY OVERVIEW
    • 10.2.5 CHECKPOINT SURGICAL INC.
    • TABLE 310 CHECKPOINT SURGICAL INC.: COMPANY OVERVIEW
    • 10.2.6 RENISHAW PLC.
    • TABLE 311 RENISHAW PLC.: COMPANY OVERVIEW
    • 10.2.7 ALAFAIR BIOSCIENCES, INC.
    • TABLE 312 ALAFAIR BIOSCIENCES, INC.: COMPANY OVERVIEW
    • 10.2.8 ELECTROCORE, INC.
    • TABLE 313 ELECTROCORE, INC.: COMPANY OVERVIEW
  • *Details on Business overview, Products offered, Recent developments, MNM Views, Key strengths/right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 INDUSTRY INSIGHTS
  • 11.2 DISCUSSION GUIDE
  • 11.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.4 AVAILABLE CUSTOMIZATIONS
  • 11.5 RELATED REPORTS
  • 11.6 AUTHOR DETAILS